Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy
with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell
carcinoma. And this study will provide valuable information for further clinical trials of
preoperative Teripalimab and other immune checkpoint therapy in esophageal cancer treatment.